Все публикации

0:04:35

Update on current therapies for essential tremor

0:01:36

P2B001: a slow-release drug for Parkinson’s disease

0:01:53

Pathophysiology of REM sleep behavior disorder

0:04:56

CBT mobile apps to treat insomnia

0:01:44

Predictors of conversion from positive to negative MOG antibody status

0:01:38

Recent developments in migraine treatment

0:04:12

Predictors of recovery from post-stroke aphasia

0:06:28

Interim data from ECST-2 trial challenges surgical guidelines for carotid stenosis

0:07:22

INTERACT3 results: care bundle improves outcomes in intracerebral hemorrhage

0:03:24

Three-month outcomes for patients with chronic pain using cannabis-based medical products

0:02:18

Diagnostic challenges in atypical parkinsonian disorders

0:01:12

The impact of diet and exercise on adult hippocampal neurogenesis

0:07:14

Advocating for medical cannabis access and acceptance in the UK

0:03:02

Improvements to levodopa-based treatments for Parkinson’s disease

0:05:20

Results of ocrelizumab in treatment-naïve patients with early relapsing MS

0:05:17

Anti-obesity drugs increase adult neurogenesis in the hypothalamus

0:03:00

Extracellular vesicles in Parkinson’s disease

0:03:22

MND-SMART: the adaptive platform trial investigating potential treatments for MND

0:04:42

Developing a gene therapy for focal cortical dysplasia type II

0:01:59

What is a tauopathy?

0:01:22

Investigating the glymphatic system in neurodegenerative diseases

0:02:03

What is the future of immunotherapy in Parkinson’s disease?

0:02:37

Novel brain penetrant capsids for Parkinson’s disease gene therapy

0:02:07

Future of tau-targeting immunotherapies in Alzheimer’s disease